5 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix http://www.zacks.com/stock/news/417279/the-zacks-analyst-blog-highlights-johnson-johnson-apple-goldman-sachs-ibm-and-netflix?cid=CS-ZC-FT-417279 May 21, 2019 - The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs http://www.zacks.com/research-daily/416895/top-analyst-reports-for-johnson-johnson-apple-goldman-sachs?cid=CS-ZC-FT-416895 May 20, 2019 - Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
AbbVie's Brain Cancer Candidate Fails in Phase III Study http://www.zacks.com/stock/news/416716/abbvies-brain-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-416716 May 20, 2019 - AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Did Geron's Big Announcement Just Go Unnoticed? https://www.fool.com/investing/2019/05/16/did-gerons-big-announcement-just-go-unnoticed.aspx?source=iedfolrf0000001 May 16, 2019 - Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.

Pages: 1

Page 1